In a recent interview with CU Innovations, Dr. Achim Klug, Professor of Physiology & Biophysics at CU Anschutz, shared exciting developments about a revolutionary treatment for age-related hearing loss that challenges everything we thought we knew about hearing restoration.
The Problem With Current Solutions
Dr. Klug's work addresses a widespread yet often misunderstood condition: central hearing loss, which affects the brain rather than the ears themselves. If you've ever struggled to follow a conversation in a noisy restaurant despite having "perfect hearing" according to traditional tests, you've experienced this phenomenon firsthand. The frustrating reality is that conventional hearing aids can't help with this condition because they're designed to amplify sound at the ear level, not address how the brain processes and filters auditory information.
This affects an astounding number of people—approximately one-third of adults between 40 and 65, and half of those 65 and older. That's millions of people who currently have no effective treatment options.
-
A Novel Approach: Drug Plus Sound
What makes Dr. Klug's research particularly innovative is the treatment approach itself: a one-month combination therapy pairing medication with specially engineered sound. The goal isn't just temporary relief but lasting, long-term improvement in the brain's ability to isolate sounds of interest from background noise.
The treatment is designed to be simple, non-invasive, and benign—critical factors for widespread adoption, especially among older populations who may already be managing multiple health conditions.
From Bats to Breakthrough
Dr. Klug's path to this discovery is as fascinating as the treatment itself. His career began studying echolocation in bats, drawn initially by scientific curiosity and the opportunity to work in exotic locations. But he recognized the profound medical relevance of these brain circuits in humans and pivoted to understanding what changes during aging—and crucially, how to reverse it.
His motivation is deeply personal and urgent. As he notes in the interview, affected listeners consistently tell him to "work faster" because they desperately want this treatment. That human element drives the research forward.
What's Next?
The timeline is remarkably encouraging. Dr. Klug's team recently received FDA approval for Phase 2 clinical trials and planned to begin enrolling participants in October. The technology has been licensed to Parley Neurotech Inc., led by Dr. Sam Budoff as CEO, and the team is actively seeking venture capital investment to accelerate development and bring the treatment to market.
Perhaps most exciting are the potential future applications. While the current focus is on age-related hearing loss, the same treatment may benefit people with autism, individuals who've experienced significant noise exposure (including factory workers and military veterans), and those suffering from tinnitus. Each of these populations represents millions more people who could potentially benefit from this groundbreaking approach.
A Paradigm Shift in Hearing Medicine
What stands out most about Dr. Klug's work is that it represents the first treatment for hearing loss caused by the brain rather than the ears. This isn't just an incremental improvement—it's a fundamental shift in how we approach hearing restoration, opening up an entirely new category of therapeutic intervention.
For the millions of people who struggle to hear clearly in everyday situations despite normal ear function, this research offers genuine hope. The combination of solid science, FDA approval, and a clear path to commercialization suggests we may soon see a world where central hearing loss is no longer an untreatable condition but a manageable one.
As Dr. Klug and his team move forward with clinical trials, they're not just developing a new treatment—they're potentially transforming the lives of millions of people who've been told there's nothing that can help them. That's the kind of innovation that deserves our attention and support.
